Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

952
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
952
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

924
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
924
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

811
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
811
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

60
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid...
60
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

1.9K
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
1.9K
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

197
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
197

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing Histologic Entry Criteria for Clinical Trials in Celiac Disease Involving Gluten Challenge.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Celiac Disease.

The New England journal of medicine·2026
Same author

Small intestinal microbial fiber metabolism dysfunction in celiac disease.

Nature communications·2026
Same author

Evaluating the Clinical Relevance of Elevated Mucosal Mast Cells in the Gastrointestinal Tract.

Journal of clinical gastroenterology·2025
Same author

Drugs in Development and Clinical Trials for Celiac Disease.

Gastrointestinal endoscopy clinics of North America·2025
Same author

Immunology in Celiac Disease.

Gastrointestinal endoscopy clinics of North America·2025

Related Experiment Video

Updated: Apr 13, 2026

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

20.8K

Drug-induced enteropathy.

Eric V Marietta, Amanda Cartee, Abdul Rishi

    Digestive Diseases (Basel, Switzerland)
    |May 1, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Olmesartan, a blood pressure medication, can cause severe diarrhea and enteropathy, mimicking celiac disease. Discontinuation often resolves symptoms, but awareness is crucial for diagnosis.

    More Related Videos

    Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
    08:58

    Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

    Published on: January 5, 2017

    13.0K
    Author Spotlight: Enhancing Understanding and Treatment Strategies with the NEC-on-a-Chip Model
    06:51

    Author Spotlight: Enhancing Understanding and Treatment Strategies with the NEC-on-a-Chip Model

    Published on: July 28, 2023

    2.0K

    Related Experiment Videos

    Last Updated: Apr 13, 2026

    Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
    08:24

    Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

    Published on: May 2, 2018

    20.8K
    Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
    08:58

    Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

    Published on: January 5, 2017

    13.0K
    Author Spotlight: Enhancing Understanding and Treatment Strategies with the NEC-on-a-Chip Model
    06:51

    Author Spotlight: Enhancing Understanding and Treatment Strategies with the NEC-on-a-Chip Model

    Published on: July 28, 2023

    2.0K

    Area of Science:

    • Gastroenterology
    • Pharmacology
    • Internal Medicine

    Background:

    • Medications can induce diarrhea through increased motility, inflammation, or enteropathy.
    • Olmesartan and mycophenolic acid are implicated in drug-induced enteropathy and chronic diarrhea.
    • Recognizing these drug-induced conditions is critical to prevent long-term complications.

    Purpose of the Study:

    • To review drug-associated enteropathies, focusing on olmesartan and mycophenolic acid.
    • To highlight the clinical presentation and diagnostic considerations of olmesartan-induced enteropathy.
    • To differentiate drug-induced enteropathy from other gastrointestinal conditions like celiac disease.

    Main Methods:

    • A comprehensive review of published literature and internal findings.
    • Analysis of case reports and clinical data on drug-induced enteropathies.
    • Comparative histological analysis between drug-induced enteropathy and celiac disease.

    Main Results:

    • Olmesartan use is linked to enteropathy in a subset of patients, causing severe diarrhea, dehydration, and potential organ failure.
    • Typical olmesartan-associated enteropathy patients are older Caucasians, often obese, with prolonged drug exposure.
    • Histological features of olmesartan enteropathy resemble celiac disease; discontinuation improves symptoms, though healing varies.
    • Mycophenolate mofetil is also associated with drug-induced enteropathy, particularly in transplant patients.

    Conclusions:

    • Olmesartan can cause severe, though rare, drug-associated enteropathy, necessitating consideration in patients with unexplained severe diarrhea and weight loss.
    • Olmesartan-induced enteropathy shares histological similarities with celiac disease, requiring careful evaluation of medication history in celiac diagnoses.
    • Prompt recognition and discontinuation of the offending drug are key to managing drug-induced enteropathies.